Trial · NCT00208767
Effect of Valsartan on Carotid Artery Disease
NCT00208767, Phase 2, Completed, Emory University; results first posted 2014-09-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Valsartan on Carotid Artery Disease. Trials, record NCT00208767. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00208767
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Valsartan on Carotid Artery Disease
- NCT number
- NCT00208767
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 120 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Carotid Artery Diseases, Atherosclerosis
- Interventions
- Valsartan, Placebo
- First posted
- 2005-09-21
- Last updated
- 2015-12-08
- Results first posted
- 2014-09-19
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years | Baseline, 2 years | The PI will measure carotid artery thickening with magnetic resonance imaging. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years | Baseline, 2 years | mm2 | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years | Valsartan | -6.7 | Standard Deviation 2.4 | mm2 | |
| Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years | Placebo | 3.4 | Standard Deviation 3.1 | mm2 |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Valsartan | 80 | |
| Overall Study | STARTED | Placebo | 40 | |
| Overall Study | COMPLETED | Valsartan | 53 | |
| Overall Study | COMPLETED | Placebo | 33 | |
| Overall Study | NOT COMPLETED | Valsartan | 27 | |
| Overall Study | NOT COMPLETED | Placebo | 7 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | Respiratory, thoracic and mediastinal disorders | Valsartan | 1 | 80 | 1 |
| serious | Death | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 40 | 0 |
| serious | Stroke | Cardiac disorders | Valsartan | 1 | 80 | 1 |
| serious | Stroke | Cardiac disorders | Placebo | 0 | 40 | 0 |
| serious | Majory injury/accident | Injury, poisoning and procedural complications | Valsartan | 1 | 80 | 1 |
| serious | Majory injury/accident | Injury, poisoning and procedural complications | Placebo | 0 | 40 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Valsartan | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Valsartan | 0 | 80 |
| Total, other adverse events | Placebo | 0 | 40 |
| Total, serious adverse events | Valsartan | 3 | 80 |
| Total, serious adverse events | Placebo | 0 | 40 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Valsartan vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00208767
GET https://conductscience.org/api/trials/v1/NCT00208767/registered